1. Home
  2. POM vs ACRV Comparison

POM vs ACRV Comparison

Compare POM & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

POM

POMDOCTOR LIMITED American Depositary Shares

N/A

Current Price

$0.31

Market Cap

47.2M

ML Signal

N/A

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.56

Market Cap

52.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POM
ACRV
Founded
2015
2018
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.2M
52.4M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
POM
ACRV
Price
$0.31
$1.56
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
629.7K
597.0K
Earning Date
05-03-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$1.05
52 Week High
$6.43
$3.56

Technical Indicators

Market Signals
Indicator
POM
ACRV
Relative Strength Index (RSI) 52.54 50.01
Support Level $0.28 $1.49
Resistance Level $0.43 $1.86
Average True Range (ATR) 0.04 0.11
MACD 0.00 0.01
Stochastic Oscillator 68.97 67.86

Price Performance

Historical Comparison
POM
ACRV

About POM POMDOCTOR LIMITED American Depositary Shares

Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: